26.75
                                            Zai Lab Limited Adr Aktie (ZLAB) Neueste Nachrichten
Keeping an Eye on Nine Energy Service Inc (NINE) After Insider Trading Activity - knoxdaily.com
Zai Lab (NasdaqGM:ZLAB): Evaluating Valuation Following Promising Trial Results and Phase 3 Progress - Sahm
EBITDA per share of Zai Lab Ltd. Sponsored ADR – GETTEX:1ZL - TradingView
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zai Lab (ZLAB) to Release Quarterly Earnings on Thursday - MarketBeat
Zai Lab Announces Participation in Investor Conferences in November and December 2025 - The Globe and Mail
Zai Lab Announces Participation in Investor Conferences in September 2025 - FinancialContent
Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6%Time to Sell? - MarketBeat
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study - Business Wire
Q3 Earnings Estimate for Zai Lab Issued By Leerink Partnrs - MarketBeat
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - MSN
Zai Lab Secures RMB300 Million Debt Facility - The Globe and Mail
[8-K] Zai Lab Ltd Reports Material Event | ZLAB SEC FilingForm 8-K - Stock Titan
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - The Globe and Mail
Zai Lab (NASDAQ:ZLAB) Trading Down 6.2%Here's What Happened - MarketBeat
Late‑breaking Phase 1 data for Zoci: Zai Lab to present DLL3‑targeted ADC results at AACR Oct 24, 2025 - Stock Titan
Operating cash flow per share of Zai Lab Ltd. Sponsored ADR – BER:1ZL - TradingView
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire
Trip.com Group LimitedAmerican Depositary Shares (NQ: - FinancialContent
Is Zai Lab's Valuation Justified as Revenue Growth Lags the Biotech Industry (ZLAB)? - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks - TradingView
Zai Lab Limited Announces Equity Incentive Grants to Employees - MSN
Zai Lab (NASDAQ:ZLAB) Shares Gap UpStill a Buy? - MarketBeat
Zai Lab Limited Depositary Receipt Stock Analysis and ForecastStochastic Oscillator Alerts & High Profit Trading Signals - Early Times
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
How robust is Anheuser Busch Inbev SA Sponsored ADR stock financial position2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Zai Lab Limited Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsZLAB - ACCESS Newswire
Acadian Asset Management LLC Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Levi & Korsinsky Reminds Shareholders of an Investigation into Zai Lab Limited (ZLAB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Lost Money on Zai Lab Limited (ZLAB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Consensus Price Target from Analysts - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Zai Lab Limited (ZLAB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Insider Buying: Zai Lab (NASDAQ:ZLAB) Insider Purchases 10,000 Shares of Stock - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average PT from Brokerages - Defense World
Woodline Partners LP Sells 558,781 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap DownTime to Sell? - MarketBeat
Zai Lab Limited ADR (NASDAQ: ZLAB) Is Up 14.37% – Is It Capable Of A Rally? - stocksregister.com
FY2026 EPS Estimates for Zai Lab Reduced by Leerink Partnrs - MarketBeat
Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB) - 富途牛牛
Raymond James Financial Inc. Boosts Holdings in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Cubist Systematic Strategies LLC Increases Stake in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
Zai Lab under pressure over clinical results and rival drugs - thebambooworks.com
Why Zai Lab (ZLAB) Is Down 5.5% After Diminished Final Results for Bemarituzumab in Gastric Cancer - Sahm
Zai Lab FY2026 EPS Forecast Lowered by Leerink Partnrs - Defense World
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):